OLMA - Olema Pharma provides clinical update for its OP-1250 treatment for breast cancer

Olema Pharmaceuticals (NASDAQ:OLMA) on Thursday announced a clinical update for its lead candidate OP-1250 for the treatment of metastatic breast cancer. In its phase 1b dose expansion of OP-1250 as a monotherapy, OLMA said it observed favorable tolerability in the 30 patients enrolled. OLMA also said no grade 3/4 instance of neutropenia was observed in the participants. Neutropenia is characterized by an abnormally low count of a type of white blood cell called neutrophils, which are important for fighting certain infections, especially those caused by bacteria. H.C. Wainwright upgraded the stock to a buy rating, as it believed that the lack of grade 3/4 neutropenia cases was a "huge positive". The brokerage said that it believed if additional cases of neutropenia occurred, then it would make it challenging for OP-1250 to advance to the upfront setting in combination with CDK4/6 inhibitors. OLMA also said its phase 1b combination trial with

For further details see:

Olema Pharma provides clinical update for its OP-1250 treatment for breast cancer